BERKELEY, CA (UroToday.com) - Renal cell carcinoma represents a potentially lethal cancer that has a propensity for metastatic spread. The most frequent sites of metastasis are the lung, lymph nodes, liver, bone, and adrenal glands.
Ampullary metastasis of renal cell carcinoma is a rare entity. The treatment and prognosis is yet unknown. This case report gives us a new treatment choice, in which the primary carcinoma of the kidney and ampullary metastasis tumor were removed simultaneously. The surgery is proved to be effective with no post-operative complications occurrence, and the patient has survived for more than 5 years now. Thus surgical resection of primary and metastatic tumor may be a good choice for the patient with a solidary tumor that is caused by the metastasis of renal cell carcinoma.
In the past few years, several targeted therapies have been approved by the U.S. Food and Drug Administration for the treatment of advanced renal cell carcinoma. This has led to an improvement in the progression-free survival and quality of life for these patients. As the patient in this case report cannot afford the high medical costs of targeted therapies, he just received immunotherapy (IFN-α-2b) after radical nephrectomy. To improve progression-free survival, targeted therapies -- for example sorafenib or sunitinib -- are more suitable for this patient.
Due to the low incidence of ampullary metastasis of renal cell carcinoma, meta-analysis is certainly needed to accurately and objectively assess the role of surgical management for the patient with this type of disease.
Jiaobo Zhai, MD as part of Beyond the Abstract on UroToday.com. This initiative offers a method of publishing for the professional urology community. Authors are given an opportunity to expand on the circumstances, limitations etc... of their research by referencing the published abstract.
Beijing Jishuitan Hospital, Beijing 100035, China